| Remoxipride | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Remoxipride | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Remoxipride | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Remoxipride | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | |
| Remoxipride | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Remoxipride | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Remoxipride | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | |
| Remoxipride | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04024 | cAMP signaling pathway | 1.02E-02 | 5 | P42338, P0DP23, P04049, Q13370, Q13009 | PIK3CB, CALM1, RAF1, PDE3B, TIAM1 | More | |
| Remoxipride | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | |
| Remoxipride | hsa04071 | Sphingolipid signaling pathway | 3.35E-03 | 5 | P04049, P21453, Q9H228, P01375, Q13362 | RAF1, S1PR1, EDG8, TNF, PPP2R5C | More | |
| Remoxipride | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Remoxipride | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Remoxipride | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Remoxipride | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Remoxipride | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | |
| Remoxipride | hsa04360 | Axon guidance | 5.32E-03 | 5 | P20827, O95631, P42338, P23528, P04049 | EFNA1, NTN1, PIK3CB, CFL1, RAF1 | More | |
| Remoxipride | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04612 | Antigen processing and presentation | 3.75E-04 | 8 | P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | |
| Remoxipride | hsa04613 | Neutrophil extracellular trap formation | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04621 | NOD-like receptor signaling pathway | 2.27E-02 | 9 | Q9H1Y0, P43490, O00463, Q05823, P01375, P49913, P59665, P59666, P12838 | ATG5, PBEF1, TRAF5, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Remoxipride | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04650 | Natural killer cell mediated cytotoxicity | 3.52E-06 | 10 | P01375, O60880, P20963, P04049, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH2D1A, CD247, RAF1, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | |
| Remoxipride | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Remoxipride | hsa04659 | Th17 cell differentiation | 4.38E-02 | 4 | P42224, P14784, P40189, P08238 | STAT1, IL2RB, IL6ST, HSP90AB1 | More | |
| Remoxipride | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04666 | Fc gamma R-mediated phagocytosis | 1.31E-02 | 4 | P42338, P04049, P23528, P14598 | PIK3CB, RAF1, CFL1, NCF1 | More | |
| Remoxipride | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Remoxipride | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04722 | Neurotrophin signaling pathway | 7.10E-03 | 4 | P04049, P49841, O43524, P48023 | RAF1, GSK3B, FOXO3, FASLG | More | |
| Remoxipride | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Remoxipride | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Remoxipride | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Remoxipride | hsa04914 | Progesterone-mediated oocyte maturation | 1.31E-02 | 4 | P42338, Q13370, P08238, P04049 | PIK3CB, PDE3B, HSP90AB1, RAF1 | More | |
| Remoxipride | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04919 | Thyroid hormone signaling pathway | 4.33E-03 | 3 | P04049, P26678, P08237 | RAF1, PLN, PFKM | More | |
| Remoxipride | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04924 | Renin secretion | 2.98E-03 | 4 | P22694, P07550, Q13370, P0DP23 | PRKACB, ADRB2, PDE3B, CALM1 | More | |
| Remoxipride | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | |
| Remoxipride | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Remoxipride | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Remoxipride | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Remoxipride | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Remoxipride | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Remoxipride | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Remoxipride | hsa05144 | Malaria | 1.72E-03 | 4 | P60033, P01375, P35443, P26718 | CD81, TNF, THBS4, KLRK1 | More | |
| Remoxipride | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Remoxipride | hsa05150 | Staphylococcus aureus infection | 1.02E-03 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | |
| Remoxipride | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | |
| Remoxipride | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | |
| Remoxipride | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | |
| Remoxipride | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Remoxipride | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05212 | Pancreatic cancer | 2.44E-03 | 4 | P42338, P04049, P42224, O75293 | PIK3CB, RAF1, STAT1, GADD45B | More | |
| Remoxipride | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05214 | Glioma | 1.88E-03 | 4 | P0DP23, P04049, P42338, O75293 | CALM1, RAF1, PIK3CB, GADD45B | More | |
| Remoxipride | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Remoxipride | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Remoxipride | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Remoxipride | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Remoxipride | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
